Psilocybin to target persistent concussion symptoms in Australia's first clinical trial

Article excerpt

Monash University researchers have begun Australia's first clinical trial testing whether psilocybin, a psychedelic drug, can treat persistent post-concussion symptoms. The trial marks a significant shift in how the medical establishment approaches lingering concussion effects, headaches, dizziness, cognitive problems, that don't respond to conventional therapies. Psilocybin has shown promise in early research for neuroplasticity and mood disorders, and researchers believe it may help the brain reorganize and heal after traumatic injury. The study will enroll patients with chronic post-concussion syndrome and measure outcomes across multiple cognitive and physical domains. This work positions Australia among a growing number of countries exploring psychedelic-assisted treatments within regulated clinical frameworks.